Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | CDC25A | P30304 | 1/20 | 0.40 |
| ▸ | CDC25B | P30305 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL11599708 | 0.85 | KDM4E (0.49) | TSHRALDH1A1SLC7A5MAPTRAB9A | |
| Bromide SCHEMBL7898722 | 0.85 | XDH (0.50) | TSHRALDH1A1SLC7A5MAPTRAB9A | |
| Bromide SCHEMBL8899989 | 0.84 | P4HB (0.46) | TSHRALDH1A1SLC7A5MAPTRAB9A | |
| Bromide SCHEMBL8323844 | 0.84 | DPP4 (0.47) | TSHRALDH1A1SLC7A5MAPTRAB9A | |
| Bromide SCHEMBL7292931 | 0.84 | MAPT (0.47) | TSHRALDH1A1SLC7A5MAPTRAB9A | |
| Bromide SCHEMBL10980300 | 0.84 | KDM4E (0.49) | TSHRALDH1A1SLC7A5MAPTRAB9A | |
| Bromide SCHEMBL7902023 | 0.83 | CA1 (0.50) | PPARGPPARATSHRALDH1A1SLC7A5 | |
| Bromide SCHEMBL2316144 | 0.80 | VCAM1 (0.49) | TSHRALDH1A1PDK1MAPTMEN1 | |
| Hydrochloric Acid SCHEMBL7524637 | 0.80 | CA1 (0.50) | PPARGPPARATSHRALDH1A1SLC7A5 | |
| Bromide SCHEMBL3868509 | 0.80 | KDM4E (0.41) | PPARGPPARATSHRALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981933-B2 | Histone deacetylase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-04-20 | — | — | US | disclosed |
| CN-105120860-B | Histone deacetylase inhibitors | 生物马林药物股份有限公司 | 2021-01-26 | — | — | CN | disclosed |
| CN-111747948-A | Histone deacetylase inhibitors | 生物马林药物股份有限公司 | 2020-10-09 | — | — | CN | disclosed |
| EP-3695836-A1 | HISTONE DEACETYLASE INHIBITORS | BioMarin Pharmaceutical Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20200148704-A1 | HISTONE DEACETYLASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2020-05-14 | — | — | US | disclosed |
| EP-2968251-B1 | HISTONE DEACETYLASE INHIBITORS | BIOMARIN PHARM INC (US) | 2020-02-12 | — | — | EP | disclosed |
| EP-3524324-A1 | HISTONE DEACETYLASE INHIBITORS | BioMarin Pharmaceutical Inc. (US) | 2019-08-14 | — | — | EP | disclosed |
| US-20190233439-A1 | HISTONE DEACETYLASE INHIBITORS | REPLIGEN CORPORATION | 2019-08-01 | — | — | US | disclosed |
| US-10301323-B2 | Histone deacetylase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-10280182-B2 | Histone deacetylase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-20150158884-A1 | HISTONE DEACETYLASE INHIBITORS | BIOMARIN PHARM INC (US) | 2015-06-11 | — | — | US | disclosed |
| US-8957066-B2 | Histone deacetylase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2015-02-17 | — | — | US | disclosed |
| WO-2014152444-A1 | HISTONE DEACETYLASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140051680-A1 | Histone Deacetylase Inhibitors | REPLIGEN CORPORATION (US) | 2014-02-20 | — | — | US | disclosed |
| EP-2680694-A1 | HISTONE DEACETYLASE INHIBITORS | REPLIGEN CORPORATION (US) | 2014-01-08 | — | — | EP | disclosed |
| US-20130317003-A1 | Histone Deacetylase Inhibitors | BIOMARIN PHARMACEUTICAL INC. | 2013-11-28 | — | — | US | disclosed |
| WO-2012118782-A1 | HISTONE DEACETYLASE INHIBITORS | REPLIGEN CORPORATION (US) | 2012-09-07 | — | — | WO | disclosed |
| EP-0663391-B1 | Sulphuric acid esters of sugar alcohols for the treatment of arteriosclerotic changes in the vascular walls | HOFFMANN LA ROCHE (CH) | 1997-04-09 | — | — | EP | disclosed |
| US-5521160-A | COMPOUNDS FOR TREATMENT OF ATHERIOSCLEROSIS IN BLOOD VESSELS AND PREVENTION OF RESTENOSIS AFTER ANGIOPLASTY | HOFFMANN-LA ROCHE INC. (US) | 1996-05-28 | — | — | US | disclosed |
| EP-0663391-A1 | Sulphuric acid esters of sugar alcohols for the treatment of arteriosclerotic changes in the vascular walls | F. HOFFMANN-LA ROCHE AG (CH) | 1995-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233439-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC2, HDAC3 | PPARG 1614/4885PPARA 1784/4885TSHR 3182/4885 |
| US-20140051680-A1 | Histone Deacetylase Inhibitors | HDAC1, HDAC2, HDAC3 | PPARG 1660/4885PPARA 1866/4885TSHR 3136/4885 |
| US-10301323-B2 | Histone deacetylase inhibitors | HDAC1, HDAC2, HDAC3 | PPARG 1614/4885PPARA 1784/4885TSHR 3182/4885 |
| US-20200148704-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC2, HDAC3 | PPARG 1614/4885PPARA 1784/4885TSHR 3182/4885 |
| US-20150158884-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC2, HDAC3 | PPARG 1614/4885PPARA 1784/4885TSHR 3182/4885 |
| US-10280182-B2 | Histone deacetylase inhibitors | HDAC1, HDAC2, HDAC3 | PPARG 1614/4885PPARA 1784/4885TSHR 3182/4885 |
| US-10981933-B2 | Histone deacetylase inhibitors | HDAC1, HDAC2, HDAC3 | PPARG 1614/4885PPARA 1784/4885TSHR 3182/4885 |
| US-20130317003-A1 | Histone Deacetylase Inhibitors | HDAC1, HDAC2, HDAC3 | PPARG 1614/4885PPARA 1784/4885TSHR 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.